- Home
- GIFT vs IGC Comparison
GIFT vs IGC Comparison
Compare GIFT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIFT
- IGC
- Stock Information
- Founded
- GIFT 1999
- IGC 2005
- Country
- GIFT United States
- IGC United States
- Employees
- GIFT N/A
- IGC N/A
- Industry
- GIFT Catalog/Specialty Distribution
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- GIFT Consumer Discretionary
- IGC Health Care
- Exchange
- GIFT Nasdaq
- IGC Nasdaq
- Market Cap
- GIFT 40.4M
- IGC 33.5M
- IPO Year
- GIFT N/A
- IGC N/A
- Fundamental
- Price
- GIFT $1.05
- IGC $0.34
- Analyst Decision
- GIFT Strong Buy
- IGC Strong Buy
- Analyst Count
- GIFT 1
- IGC 2
- Target Price
- GIFT $4.00
- IGC $3.88
- AVG Volume (30 Days)
- GIFT 227.7K
- IGC 1.1M
- Earning Date
- GIFT 08-19-2025
- IGC 08-15-2025
- Dividend Yield
- GIFT N/A
- IGC N/A
- EPS Growth
- GIFT N/A
- IGC N/A
- EPS
- GIFT N/A
- IGC N/A
- Revenue
- GIFT $89,689,155.00
- IGC $1,271,000.00
- Revenue This Year
- GIFT $12.22
- IGC $15.26
- Revenue Next Year
- GIFT $13.86
- IGC $3.41
- P/E Ratio
- GIFT N/A
- IGC N/A
- Revenue Growth
- GIFT 6.13
- IGC N/A
- 52 Week Low
- GIFT $0.82
- IGC $0.25
- 52 Week High
- GIFT $3.93
- IGC $0.48
- Technical
- Relative Strength Index (RSI)
- GIFT N/A
- IGC 46.47
- Support Level
- GIFT N/A
- IGC $0.35
- Resistance Level
- GIFT N/A
- IGC $0.36
- Average True Range (ATR)
- GIFT 0.00
- IGC 0.02
- MACD
- GIFT 0.00
- IGC -0.01
- Stochastic Oscillator
- GIFT 0.00
- IGC 11.87
About GIFT RDE Inc. Common Stock
Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.